ChemoCentryx (ChemoCentryx) 5-Year Dividend Growth Rate : 0.00% (As of Jun. 2022)

View and export this data going back to 2012. Start your Free Trial

What is ChemoCentryx 5-Year Dividend Growth Rate?

ChemoCentryx's Dividends per Share for the three months ended in Jun. 2022 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

ChemoCentryx's Dividend Payout Ratio for the three months ended in Jun. 2022 was 0.00. As of today, ChemoCentryx's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of ChemoCentryx's 5-Year Dividend Growth Rate

For the Biotechnology subindustry, ChemoCentryx's 5-Year Dividend Growth Rate, along with its competitors' market caps and 5-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ChemoCentryx's 5-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ChemoCentryx's 5-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where ChemoCentryx's 5-Year Dividend Growth Rate falls into.

ChemoCentryx 5-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

ChemoCentryx (NAS:CCXI) 5-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

ChemoCentryx's Dividend Payout Ratio for the quarter that ended in Jun. 2022 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Jun. 2022 )	/	EPS without NRI (Q: Jun. 2022 )
	=	0	/	-0.44
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ChemoCentryx 5-Year Dividend Growth Rate Related Terms

Thank you for viewing the detailed overview of ChemoCentryx's 5-Year Dividend Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

ChemoCentryx (ChemoCentryx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ChemoCentryx Inc (NAS:CCXI) » Definitions » 5-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

835 Industrial Road, Suite 600, San Carlos, CA, USA, 94070

Website

https://www.chemocentryx.com

ChemoCentryx Inc is a biopharmaceutical company involved in the discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer. The company's approach is to target the chemoattractant system, defined as a network of molecules (for example, chemokine ligands, their associated receptors, and chemoattractant receptors) known to cause inflammation. The targeted therapeutic areas are an antineutrophil cytoplasmic antibody, atypical hemolytic uremic syndrome, immunoglobulin A-mediated nephropathy (rare diseases category), pancreatic cancer, chronic kidney disease, psoriasis, rheumatoid arthritis, asthma, Crohn's disease, inflammatory bowel disease, and others.

Executives

Susan M Kanaya	officer: SVP Finance, CFO & Secretary	850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Thomas J. Schall	director, 10 percent owner, officer: President, CEO and Director	850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Jennifer Lyn Herron	director	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
James L Tyree	director	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064-6400
Yi Ching Yau	officer: SVP, Finance & Acctg Officer	C/O BRIDGEBIO PHARMA, INC., 421 KIPLING STREET, PALO ALTO CA 94301
David E. Wheadon	director	C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Vifor (international) Ltd	10 percent owner	RECHENSTRASSE 37, ST. GALLEN V8 9000
Tausif Butt	officer: EVP, Chief Operating Officer	C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Geoffrey M. Parker	director	15 RIORDAN PLACE, MENLO PARK CA 94025
Thomas A. Edwards	director	C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Markus J. Cappel	officer: CBO and Treasurer	850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Pui San Kwan	officer: Principal Acctg Officer	850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Rajinder Singh	officer: SVP, Research	C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Rita Jain	director	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Vifor Pharma Ltd.	10 percent owner	UNTERMATTWEG 8, BERNE V8 CH-3027